Oncology development

Oncology Brief: CAR-T Delivery, Phase 3 Funding and Biomarker Trials

Hemogenyx CAR-T delivery, Cardiff Phase 3 funding and Immuneering–Astellas biomarker studies lead Lampgen’s November 12, 2026 oncology briefing.

By Lampgen Clinical Research

A protocol sheet leads toward an infusion room, with three independent execution questions: reach infusion, fund Phase 3 and identify eligible patients.
AI-generated conceptual editorial illustration. These are three independent investigational programs, not stages of a single trial or an actual study protocol.
Reach the patientMake the study executable
November 12, 2026: three independent programs expose different clinical-development decisions. Sponsor-reported clinical claims remain preliminary.

What the source reported

Five consented patients progressed before their CAR-T product could be completed. A colorectal cancer program is preparing a registrational trial that still requires financing. Two pancreatic cancer combinations will depend on identifying tumors expressing a specified biomarker. These are the three lead stories in Lampgen’s November 12 oncology scan. [1–3]

This edition reviews 11 company releases dated November 12, 2026. Clinical claims are sponsor-reported. The operational questions below are Lampgen’s interpretation; they do not establish that any sponsor failed its obligations. Edited by Tommy Lampley, Jr., M.S.

Hemogenyx: count the patients who never reach infusion

Hemogenyx treated the first adult at the second HG-CT-1 dose level in relapsed or refractory acute myeloid leukemia. Five previously consented patients progressed before manufacture could finish; two also had poor-quality starting cells. The initial three treated patients had no reported dose-limiting toxicities or immune effector cell-associated neurotoxicity syndrome. This is early Phase 1 evidence, not an established safety or efficacy profile. [1]

The delivery question is how patients move from consent through collection, manufacturing, product release and infusion while their disease changes. Review elapsed time and reasons for attrition at each step, including patients removed before treatment. Keep the denominator visible: patients consented, collected, manufactured and infused answer different questions.

The release does not provide a complete denominator and timing analysis for every stage. It therefore cannot support a manufacturing-failure rate, an attrition percentage or a conclusion that manufacturing caused progression. Investigator-led decisions about disease management during the interval belong within the protocol and clinical oversight process.

Next evidence to watch: recruitment through the second cohort, safety at the higher dose, and a fuller account of the time and reasons behind losses before infusion. The patient impact could be substantial if more eligible people can reach treatment, but that improvement has not yet been demonstrated.

Cardiff: a Phase 3 target needs a funded operating plan

Cardiff reported median progression-free survival still unreached with 30 mg onvansertib plus FOLFIRI/bevacizumab in first-line RAS-mutated metastatic colorectal cancer, versus approximately 11 months in pooled standard-of-care arms. Its potential Q1 2027 Phase 3 start remains conditional on additional financing. Preparation includes vendors, clinical supply and a RAS companion diagnostic. [2]

An unreached median does not mean progression has stopped or establish the size of treatment benefit. The November update does not provide a new complete comparative table with updated arm denominators, hazard ratios, confidence intervals and safety results. Patients still receiving treatment represent a selected subset, not the whole randomized population.

Separate corporate cash runway from the funding required to deliver a registrational protocol. Before committing sites and vendors, align committed capital with startup, supply, screening, monitoring, follow-up and a plan for changed assumptions. Track financing as an explicit dependency of the study start.

Next evidence to watch: confirmed financing, the final protocol and diagnostic workflow, a verified study start and a fuller comparative data update. The practical importance is whether an encouraging signal can be tested reliably in the population intended for a future indication.

Immuneering and Astellas: the biomarker pathway is part of the study

The collaboration plans two Astellas-sponsored studies in CLDN18.2-expressing metastatic pancreatic cancer. One pairs an investigational CLDN18.2 program with atebimetinib and modified gemcitabine/nab-paclitaxel in first-line disease. The other combines a different CLDN18.2 program with atebimetinib without chemotherapy after prior treatment. Detailed protocols and timing were not disclosed. These are planned studies, not combination efficacy results. [3]

Before forecasting enrollment, teams need the final expression threshold, assay, accepted tissue source, specimen requirements and turnaround expectations. Map who retrieves outside tissue, resolves an inadequate sample and informs the investigator when eligibility can be confirmed. Those details remain questions for the eventual protocols, not requirements established by this announcement.

Record patients who cannot complete testing as well as those whose tumors do not meet the biomarker rule. Otherwise, a biological eligibility problem and a specimen-access problem can look identical in a screening report. Review referral source and geography when the data can support an access analysis. [12]

Next evidence to watch: registration and protocol details, assay specifications, dosing and safety plans, and actual enrollment. A chemotherapy-free strategy could eventually change treatment burden if benefit and tolerability are established; neither follows from a supply agreement alone.

Other new development steps

Immuneering’s separate anaplastic thyroid cancer announcement proposes a Phase 2 atebimetinib-plus-chemotherapy study. The company targets an IND submission by year-end 2026 and first dosing in mid-2027, subject to clearance. The potentially registrational description remains dependent on regulatory discussion. [4]

Apmonia treated the first participant in APM-CT001, its Phase 1/2a TAX2 study in advanced solid tumors. TAX2 targets the TSP-1/CD47 interaction. Initial safety and biomarker observations are expected in 2027; the release announced no clinical efficacy result. [5]

Aktis opened backfill cohorts at selected doses in its Nectin-4 and B7-H3 radiopharmaceutical programs while escalation continues. Preliminary AKY-1189 data are targeted for Q1 2027 and AKY-2519 data for 2027. More patients at selected doses will help characterize those doses; cohort opening itself does not establish benefit. [6]

Quarterly context and commercial updates

IMUNON targets completion of OVATION 3 enrollment in Q1 2029. Its SITC discussion refers to translational findings announced November 6, rather than a fresh November 12 efficacy readout. [7]

Eikon’s quarterly update spans EIK1001, selective PARP1 inhibitors, WRN inhibition and EIK1006. Much of the scientific material recaps October ESMO findings and an October IND submission. The date of the financial release should not become the date assigned to those underlying milestones. [8]

Lucid’s EsoGuard announcement is a commercial and reimbursement update alongside quarterly results. The release describes Medicare payments through claim-by-claim adjudication and says a MolDX coverage reconsideration remains pending. Payment activity and testing volume should be assessed separately from evidence that screening improves long-term patient outcomes. [9]

Watch the data, then the discussion: November 13–16

Cerenome says REYOBIQ ReSPECT-LM data are scheduled for presentation at SNO on Friday, November 13. It plans a review and CNSide commercial update on Monday, November 16, at 8:30 a.m. Eastern. [11]

Alpha Tau also plans a Monday, November 16, 8:30 a.m. Eastern call, following an SNO presentation, to discuss interim REGAIN results in recurrent glioblastoma. Today’s announcement is a call notice rather than a disclosed efficacy dataset. [10]

The calls overlap. Review the original presentations and study context first, then use recordings for management discussion. Assess patient numbers, follow-up, endpoints and adverse events before treating either presentation as evidence of durable clinical benefit.

What this means for trial teams

Assign ownership to the dependency that could stop the study. For a cell-therapy trial, that may be a handoff before infusion. For a registrational program, it may be a financing or supply commitment. For a biomarker study, it may be tissue retrieval and testing. Each needs a named decision owner and a way to verify that follow-up worked.

Staff for the work the protocol creates. An oncology CRA needs to trace eligibility and safety findings to the source, raise unresolved risks through the agreed process and verify documented follow-up. The study manager needs to coordinate decisions across sites, laboratories, manufacturers and other vendors. Lampgen Clinical Research provides oncology staffing and Clinical Trial Manager support around these responsibilities. [13, 14]

Sources

  1. Hemogenyx, first patient treated in second adult HG-CT-1 dose cohort, November 12, 2026
  2. Cardiff Oncology, third-quarter results and onvansertib update, November 12, 2026
  3. Immuneering, Astellas pancreatic cancer clinical collaboration, November 12, 2026
  4. Immuneering, planned atebimetinib Phase 2 study in anaplastic thyroid cancer, November 12, 2026
  5. Apmonia, first patient treated with TAX2 in APM-CT001, November 12, 2026
  6. Aktis Oncology, third-quarter results and clinical trial progress, November 12, 2026
  7. IMUNON, third-quarter development update, November 12, 2026
  8. Eikon Therapeutics, third-quarter clinical update, November 12, 2026
  9. Lucid Diagnostics, third-quarter commercial update, November 12, 2026
  10. Alpha Tau Medical, forthcoming REGAIN investor call, November 12, 2026
  11. Cerenome, forthcoming REYOBIQ and CNSide update, November 12, 2026
  12. Lampgen Clinical Insights, biomarker screening and specimen workflows
  13. Lampgen Clinical Insights, Phase 1 oncology trial staffing
  14. Lampgen Clinical Research, contract Clinical Trial Manager support

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?